A Clinical Trial Registry - India audit of listed head-and-neck cancer trials and studies from 2008-2022: A retrospective study

Author:

Roy Soumya Kanti1,Kumar Meghna1,Goyal Prachi1,Qayyumi Burhanuddin1

Affiliation:

1. Department of Surgical Oncology, Homi Bhabha Cancer Hospital and Research Center, Muzaffarpur, Bihar, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India

Abstract

ABSTRACT Background: Clinical trials are vital for advancing cancer treatment, but gaps exist in establishing ethical practices and transparency, especially in the context of head-and-neck cancers (HNCs) in India. Objectives: The primary objective of the study was to conduct a critical audit of the Clinical Trials Registry – India (CTRI) from 2008 to 2022; to quantify the number of studies and trials related to HNCs. Our secondary objective was to evaluate the credibility, accountability, and ethical advancements attributed to these registrations within India’s clinical research landscape. Materials and Methods: This was a retrospective study conducted between October 2022 and August 2023 at Homi Bhabha Cancer Hospital and Research Center, a tertiary cancer center in India. A thorough examination of the CTRI and PubMed databases was performed, encompassing 356 HNC trials registered at CTRI. Parallelly, 926 peer-reviewed publications from the leading clinical trial centers were assessed for credibility and accountability. Results: Of the 356 trials, 211 (59.3%) were interventional; however, 225 (63.2%) lacked explicit primary endpoints. Tata Memorial Center, Mumbai, India registered the maximum share with 98 (27.5%) trials registered during the period. Among the leading trial centers, notable discrepancy between CTRI registration and subsequent publication was observed, ranging from 2.2-8% across Tata Memorial Center (Mumbai), All India Institute of Medical Sciences (New Delhi), and Kasturba Medical College (Manipal). Conclusion: This audit exposed substantial ethical and transparency gaps, with a marked concentration in a few institutions within the Indian HNC clinical trials’ landscape. The study calls for urgent reforms to improve multi-institutional collaboration and ethical standards for enhanced human trials.

Publisher

Medknow

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3